FDA to Consider Easing Restrictions on Unproven Peptides Promoted by RFK Jr.
The U.S. Food and Drug Administration (FDA) announced it will hold a meeting in July 2026 to consider easing restrictions on more than half a dozen unapproved peptide injections. This decision follows repeated pledges by Health Secretary Robert F. Kennedy Jr. to loosen regulations on these substances, which have gained popularity among wellness influencers and celebrities for claims regarding muscle building, injury healing, and anti-aging. The FDA stated it would soon remove these chemicals from a restrictive list reserved for high-risk, unapproved drugs and will ask an advisory panel to review whether they can be safely produced by compounding pharmacies. Peptides under discussion include BPC-157, heavily marketed for inflammation reduction. Critics note that there is little scientific research supporting these health claims, and most peptides have not undergone rigorous safety reviews by the agency. The move aligns with Kennedy's 'Make America Healthy Again' movement, supported by figures like longevity expert Gary Brecka, who sells peptide formulas. This regulatory shift raises concerns about patient safety given the lack of established clinical evidence for many of these treatments.
Wire timeline
FDA to Consider Easing Restrictions on Unproven Peptides Promoted by RFK Jr.
The U.S. Food and Drug Administration (FDA) announced it will hold a meeting in July 2026 to consider easing restrictions on more than half a dozen unapproved peptide injections. This decision follows repeated pledges by Health Secretary Robert F. Kennedy Jr. to loosen regulations on these substances, which have gained popularity among wellness influencers and celebrities for claims regarding muscle building, injury healing, and anti-aging. The FDA stated it would soon remove these chemicals from a restrictive list reserved for high-risk, unapproved drugs and will ask an advisory panel to review whether they can be safely produced by compounding pharmacies. Peptides under discussion include BPC-157, heavily marketed for inflammation reduction. Critics note that there is little scientific research supporting these health claims, and most peptides have not undergone rigorous safety reviews by the agency. The move aligns with Kennedy's 'Make America Healthy Again' movement, supported by figures like longevity expert Gary Brecka, who sells peptide formulas. This regulatory shift raises concerns about patient safety given the lack of established clinical evidence for many of these treatments.
nbcnews